Regulatory News has published 1 story about Kasvu Therapeutics on 29 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 29 September 2026.
This page is generated from Regulatory News’ editorial coverage of Kasvu Therapeutics. It is not an advertisement.
On the record
- Company
- Kasvu Therapeutics
- Headquarters
- Helsinki, Finland
- Founded
- 2023, as a University of Helsinki spinout, based on the neuroplasticity research of Eero Castrén and Ilpo Vattulainen
- Regulator
- FDA and EU national authorities (proceeds fund IND/CTA-enabling studies for a first-in-human trial)
- Latest milestone
- €30 million Series A financing
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
